🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchSurvodutide (GCG/GLP-1) — anyone have experience? Page 3

Survodutide (GCG/GLP-1) — anyone have experience?

stefan_berlin Sat, Mar 28, 2026 at 5:44 AM 16 replies 838 viewsPage 3 of 4
RunnerRach
Member
467
2,123
Aug 2024
Boston, MA
Mar 31, 2026 at 2:31 PM#11
Dr.MetabolicMD said:
There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

Saving this. It is the first explanation that did not require me to already understand it.

49 24BenResearch_OR, MikeKY_noInsulin, Dr.RaviCardio and 46 others
Reply Quote Save Share Report
SleepDoc_PDX
Member
289
1,234
Sep 2024
Portland, OR
Apr 1, 2026 at 11:07 AM#12

Adding the clinical framing, because it changes how the question reads. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.

48 23hank_denver, carlos_SATX, sophie_paris and 45 others
Reply Quote Save Share Report
sarah.morrison
VIP Member
3,212
14,567
Jan 2024
California
Online
Apr 2, 2026 at 7:42 AM#13
Dr.RheumBOS said:
If two explanations both fit, the useful question is which one predicts something the other does not.

Careful with the causal language. Two things moving together in a period when five things changed is not a mechanism, and stating it as one makes the thread less useful to somebody reading it later.

47 22tony_orlando, Dr.NephBHM_UK, kim_atl_prep and 44 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
NicoleRaleigh
Member
356
1,567
Aug 2024
Raleigh, NC
Apr 3, 2026 at 4:17 AM#14

Adding the numbers, since they settle part of this. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.

46 21VendorMark, COA_Karl, MikeFit_NJ and 43 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Apr 4, 2026 at 12:51 AM#15

Moderator note: the sourcing question belongs in the vendor section and has been split out. No action needed from anybody.

45 20PurityPaulOR, MaxMetOK, MounjBrad and 42 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register